Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 356 matching trials from the live ClinicalTrials.gov search.
Conditions
Physical Activity, Sleep, Allogenic Hematopoietic Cell Transplant
Interventions
Fitbit, Questionnaire
Device · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cancer Survivor, Diabetes Mellitus, Hypertension
Interventions
computed tomography, cytology specimen collection procedure, laboratory biomarker analysis, questionnaire administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
45 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Duarte, California
Conditions
Heart Transplant Failure, Anesthesia
Interventions
Lung Recruitment
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Primary Heart Transplant, Heart Transplantation, Heart Transplant
Interventions
bortezomib, plasmapheresis
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Beverly Hills, California • San Francisco, California • New Haven, Connecticut + 9 more
Conditions
Cardiac Transplant Failure
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 73 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Cardiac Allograft Vasculopathy
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Not applicable Interventional Results available

Donor After Circulatory Death Heart CAP Trial

NCT04615182
Conditions
Heart Transplant
Interventions
Transplant
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more
Conditions
Congestive Heart Failure
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Palo Alto, California • Pittsburgh, Pennsylvania
Conditions
Fibrosis (Morphologic Abnormality)
Interventions
[F-18]-FAPI-74
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed No phase listed Observational

Dynamic Cardiac SPECT Imaging

NCT01934985
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
San Francisco, California
Conditions
Cardiac Allograft Vasculopathy, Heart Transplant Recipients
Interventions
Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper), Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
24
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 16 more
Terminated Phase 2Phase 3 Interventional Results available

Cardiac Safe Transplants for Systemic Sclerosis

NCT03593902
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Chicago, Illinois
Completed Early Phase 1 Interventional

Deconditioning in Transplant

NCT02611219
Conditions
Hematopoietic and Stem Cell Transplant
Interventions
General Health Module-Baseline Adolescent-Self Report (13-18 years), General Health Module-Follow Up Adolescent-Self Report (13-18 years), General Health Module-Baseline Parent Report-Adolescent (13-18 years), General Health Module-Follow Up Parent Report-Adolescent (13-18 years), General Health Module-Baseline Parent Report-School Age (5-12 years), General Health Module-Follow Up Parent Report-School Age (5-12 years), Demographic Data Form, SCT Daily Activity Log, The Functional Independence Measure for Children, Manual Muscle Testing, 3-Minute Step Test, HSCT Module-Follow Up Adolescent-Self Report (13-18 years), HSCT Module-Follow Child-Self Report (5-12 years), HSCT Module-Follow Up Parent Report-adolescent (13-18 years), HSCT Module-Follow Up Parent Report-School Age (5-12 years)
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
7 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Active, not recruiting No phase listed Observational

Surveillance HeartCare® Outcomes Registry

NCT03695601
Conditions
Heart Transplant Rejection
Interventions
Standard of Care
Other
Lead sponsor
CareDx
Industry
Eligibility
15 Years and older
Enrollment
2,743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
67
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Completed Not applicable Interventional Results available

International EXPAND Heart Pivotal Trial

NCT02323321
Conditions
Heart Transplant
Interventions
Preservation of Hearts for Transplantation
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Indianapolis, Indiana • Boston, Massachusetts + 7 more
Conditions
Heart Failure
Interventions
Mesenchymal Precursor cells (RevascorTM), Cryoprotective media alone
Biological · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
San Diego, California • Washington D.C., District of Columbia • Oak Lawn, Illinois + 12 more
Completed Phase 4 Interventional Results available

HCV Positive Heart Donors

NCT03382847
Conditions
Heart Failure
Interventions
Transplant with HCV positive donor, followed by surveillance and treatment of viremia
Combination Product
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Completed Phase 4 Interventional Results available

Letermovir Use in Heart Transplant Recipients

NCT04904614
Conditions
Cytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection, Antiviral Toxicity, Neutropenia
Interventions
Letermovir
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated No phase listed Observational Results available

Alloantibodies in Pediatric Heart Transplantation

NCT01005316
Conditions
Pediatric Heart Transplantation, Pediatric Heart Transplant Recipients
Interventions
Induction Therapy, Tacrolimus, Mycophenolate Mofetil, Intraoperative plasma exchange/pheresis, Short-term post-operative plasmapheresis, Immunoglobulins, Intravenous, Prednisone
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 4 more
Conditions
Cardiovascular Disease, Acute Rejection of Cardiac Transplant, Cardiac Transplant Rejection, Heart Transplant Failure and Rejection
Interventions
Blood Draw of up to 10 ml
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Not listed
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
8
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Chicago, Illinois + 4 more
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Busulfan, Cyclophosphamide, Echocardiography Test, Fludarabine, Haploidentical Hematopoietic Cell Transplantation, Lapine T-Lymphocyte Immune Globulin, Lumbar Puncture, Matched Unrelated Donor Hematopoietic Cell Transplantation, Melphalan, Methotrexate, Multigated Acquisition Scan, Mycophenolate Mofetil, Myeloablative Conditioning, Quality-of-Life Assessment, Questionnaire Administration, Rituximab, T-Cell Depletion Therapy, Tacrolimus, Thiotepa, Total-Body Irradiation
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 49 more
Completed Not applicable Interventional Results available

TEE Image Quality Improvement With Our Devised Probe Cover

NCT03812185
Conditions
Image Quality
Interventions
Suctioning orogastric tube which is attached to TEE probe cover
Device
Lead sponsor
Henry Ford Health System
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Heart Transplant Failure, Heart Transplant Infection
Interventions
Levothyroxine, Normal saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Heart Transplant Rejection, Graft Failure, Compliance, Patient
Interventions
Envarsus
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Dallas, Texas